Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.54 |
| ▸ | RAB9A | P51151 | 12/20 | 0.54 |
| ▸ | MTOR | P42345 | 4/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 2/20 | 0.46 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4603463 | 1.00 | NPC1 (0.54) | NPC1RAB9AMTORPIK3CAPIK3CD | |
| SCHEMBL4941254 | 0.93 | PIK3CA (0.52) | NPC1RAB9AMTORPIK3CAPIK3CD | |
| SCHEMBL4937562 | 0.93 | PIK3CA (0.54) | NPC1RAB9AMTORPIK3CAPIK3CD | |
| SCHEMBL4605158 | 0.88 | PIK3CA (0.55) | NPC1RAB9AMTORPIK3CAPIK3CD | |
| SCHEMBL4940741 | 0.87 | PIK3CA (0.53) | NPC1RAB9AMTORPIK3CAPIK3CD | |
| SCHEMBL4603465 | 0.84 | PIK3CA (0.53) | NPC1RAB9AMTORPIK3CAPIK3CD | |
| SCHEMBL5217585 | 0.84 | PIK3CA (0.49) | NPC1RAB9AMTORPIK3CAPIK3CD | |
| SCHEMBL4932993 | 0.84 | PIK3CA (0.53) | NPC1RAB9AMTORPIK3CAPIK3CD | |
| SCHEMBL4936891 | 0.83 | PIK3CA (0.62) | MTORPIK3CAPIK3CDPIK3CG | |
| SCHEMBL4605078 | 0.82 | PIK3CA (0.53) | NPC1RAB9AMTORPIK3CAPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051401-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PASS MARTIN | 2008-02-28 | — | — | US | disclosed |
| CN-101010317-A | 2, 4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer | ASTRAZENECA AB (SE) | 2007-08-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051401-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PIK3CA, TYMP, PIK3CB | NPC1 4115/4885RAB9A 1875/4885MTOR 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.